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CCN2 Expression by Tumor Stroma Is Required for
Melanoma Metastasis
James Hutchenreuther1, Krista M. Vincent2, David E. Carter3, Lynne-Marie Postovit2,4 and Andrew Leask1
Metastatic melanoma has an extremely poor prognosis with few durable remissions. The secreted matricellular
protein connective tissue growth factor (CCN2) is overexpressed in cancers including melanoma and may
represent a viable therapeutic target. However, the mechanism underlying the contribution of CCN2 to
melanoma progression is unclear. Herein, we use the highly metastatic murine melanoma cell line B16(F10) and
syngeneic mice, in which CCN2 expression is knocked out in ﬁbroblasts, to demonstrate that loss of CCN2,
either in melanoma cells or in the niche, impedes the ability of melanoma cells to invade. Speciﬁcally, loss of
CCN2 in melanoma cells diminished their ability to invade through collagen in vitro, and loss of ﬁbroblast-
derived CCN2 decreased spontaneous metastases of melanoma cells from the skin to the lungs in vivo.
Proliferation and tumor growth were not affected by loss of CCN2. CCN2-deﬁcient B16(F10) cells showed
reduced expression of the matricellular protein periostin; addition of recombinant periostin rescued the in vitro
invasion defect of these cells. Immunohistochemical analysis of CCN2-deﬁcient mice conﬁrmed loss of periostin
expression in the absence of CCN2. CCN2 and periostin mRNA levels are positively correlated with each other
and with the stromal composition of human melanoma lesions but not BRAF mutations. Thus, CCN2 promotes
invasion and metastasis via periostin and should be further evaluated as a possible therapeutic target for BRAF
inhibitor-resistant melanoma.
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INTRODUCTION
Melanoma is the second most common invasive cancer in
young adults, and the incidence of diagnosis among this
group is increasing (Reed et al., 2012). Of skin cancers,
melanoma is the most likely to metastasize, making it the
most likely to be fatal: ~ 5% of patients diagnosed with
metastatic melanoma survive for 5 years after diagnosis,
whereas patients with no metastases have a 5-year survival
rate approaching 90% (Cummins et al., 2006).
Melanocytes, protective cells found in the skin, are
subjected to assault by UV radiation on a routine basis and
thus require a strong resistance to apoptosis. Unfortunately,
this resistance is retained when melanocytes progress into the
melanoma, leaving the cancer largely unaffected by chemo-
therapy and radiotherapy (Soengas and Lowe, 2003;
Cummins et al., 2006; Gray-Schopfer et al., 2007). Given
this high resistance to conventional therapies and the
effectiveness of surgical excision in the absence of
metastasis (Cummins et al., 2006), discovering methods of
preventing metastasis is vital to improve patient survival.
For melanoma to metastasize, tumor cells must migrate
through the extracellular matrix (ECM), which largely consists
of collagen that is produced and remodeled by ﬁbroblasts
present in the stromal microenvironment. Following the
degradation of the extracellular matrix, tumor cells must
migrate by forming new adhesive sites closer to their
destination and degrading old adhesive sites further away.
The formation and degradation of these sites are governed by
integrins, and the communication between cells and their
surrounding matrix is mediated by a class of non-structural
secreted proteins known as matricellular proteins (Steeg,
2006).
Expression of the CCN family of matricellular proteins is
highly associated with certain cancers (Bleau et al., 2005;
Perbal, 2013). CCN2 (formerly known as connective tissue
growth factor) is a member of the CCN family of matricellular
proteins, which acts primarily in two ways: by directly
binding to adhesion receptors similar to integrins and by
acting as cofactors for other regulatory molecules (Chen and
Lau, 2009; Perbal, 2013). Abnormal expression patterns of
CCN proteins have been associated with progression of
breast, prostate, and pancreatic cancers (Xie et al., 2001; Yang
et al., 2005; Dornhofer et al., 2006; Sha and Leask, 2011;
Wong and Rustgi, 2013), and overexpression of CCN2 has
been associated with malignant melanoma (Sha and Leask,
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2011). CCN2 expression can also be stimulated in
surrounding tissues by the inﬂammatory response caused by
tumor formation (Coussens and Werb, 2002; Leask and
Abraham, 2006; Wong and Rustgi, 2013). Although these
observations suggest that CCN2 has a role in the metastasis of
melanoma, the majority of studies investigating CCN proteins
in cancer have only correlated expression levels of the
proteins with tumor progression without incorporating loss-of-
function studies. Recently, CCN2 was shown to be regulated
by the Hippo pathway in melanoma cell lines (Nallet-Staub
et al., 2014). However, the precise role CCN2 has in
melanoma is unclear. In particular, neither the relative roles
of tumor- or stroma-derived CCN2 in melanoma metastasis
nor the downstream effectors of CCN2 are understood.
In this report, we use a syngeneic B16F(10) murine
melanoma model (cells derived from C57 BL6 mice) (Wack
et al., 2002) and C57 BL6 mice lacking CCN2 in ﬁbroblasts to
investigate the different roles of cancer cell versus niche-
derived CCN2 in melanoma invasion and metastasis.
RESULTS
Loss of CCN2 expression by B16(F10) murine melanoma cells
results in impaired invasion but not proliferation
Initial experiments were conducted using B16(F10) mela-
noma cells that were stably transfected with either CCN2
short hairpin RNA (shRNA) or scrambled control shRNA.
Extent of CCN2 knockdown relative to glyceraldehyde-3-
phosphate dehydrogenase control was determined by real-
time PCR and western blot analyses (Figure 1a). To assess the
invasive ability of the resultant melanoma cells, B16(F10)
cells were subjected a transwell ﬁlter invasion assay. After
incubation at 37 °C for 24 hours, collagen and noninvasive
cells were removed from the inside of the transwell insert, and
the number of remaining cells was calculated. B16(F10)
melanoma cells deﬁcient in CCN2 showed markedly reduced
invasion of collagen type I compared with either wild-type
B16(F10) melanoma cells or control B16(F10) melanoma cells
stably transfected with scrambled control shRNA (Figure 1b
and c). To ensure that the loss of invasive ability with CCN2
deﬁciency was also present in human melanomas, the
transwell ﬁlter invasion assay was also used to test C8161
and C81-61 cells. Both C8161 and its poorly aggressive
counterpart were derived from metastases from the abdominal
wall, and mRNA and protein analysis revealed that C81-61
expresses signiﬁcantly less CCN2 (Seftor et al., 2005) (Figure
2a and b). Using siRNA transfection, the CCN2 expression in
C8161 cells was reduced (Figure 2a and b). Both the C8161
CCN2 siRNA cells and the C81-61 cells showed markedly
reduced invasion as compared with control C8161 cells
(Figure 2c). Of note, the reduced invasion observed with the
loss of CCN2 was not due to alterations in proliferation
(Supplementary Figure 1A online).
Loss of CCN2 expression by tumor stroma results in impaired
metastasis but not tumor growth, in vivo
To extend our in vitro data supporting a role for CCN2 in
melanoma invasion, we next ascertained the in vivo effects of
CCN2 loss on melanoma growth and invasion. To perform
these analyses, we used a syngeneic model using B16(F10)
melanoma cells (derived from C57/BL6 mice) deﬁcient or not
in CCN2 and C57/BL6 mice deﬁcient or not for CCN2 in
ﬁbroblasts. Three weeks post deletion of CCN2, we sub-
cutaneously injected mice with B16(F10) melanoma cells or
B16(F10) melanoma cells deleted for CCN2. Fourteen days
later, tumor growth and metastasis were examined. Growth of
subcutaneous tumors over 14 days was unaffected by the loss
of CCN2 expression (Supplementary Figure 1B online),
consistent with our in vitro data, suggesting that proliferation
of melanoma cells was unaffected by loss of CCN2
(Supplementary Figure 1A online). When melanoma cells
were injected into wild-type mice, loss of CCN2 in melanoma
cells did not signiﬁcantly affect metastasis to the lung,
measured using hematoxylin- and eosin-stained sections.
Indeed, loss of CCN2 expression from melanoma cells
resulted in increased metastasis in wild-type mice, likely
due to a compensatory effect of stromal CCN2 (Figure 3a and
b). However, loss of CCN2 expression by tumor stroma
resulted in a signiﬁcant reduction in metastasis, regardless of
whether CCN2 was knocked down in the melanoma cells
(Figure 3a and b). Results indicating that loss of CCN2 by
tumor stroma resulted in impaired metastasis were conﬁrmed
by gross examination of Bouin-ﬁxed lungs of mice deleted or
not for CCN2 after 21 days of tumor growth (Figure 3c and d).
Loss of CCN2 from the tumor stroma of C57 BL6 mice deleted
for CCN2 after 14 days of tumor growth was conﬁrmed by
immunohistochemical analysis using anti-CCN2 antibody
(Figure 4a). Collectively, these results indicate that CCN2
expression by the tumor stroma could compensate for loss of
CCN2 by tumor cells and that CCN2 expression by the tumor
stroma promotes metastasis in vivo.
Impaired invasive ability of CCN2-deﬁcient B16(F10) melanoma
cells is rescued by recombinant periostin
To begin to address the underlying mechanism of CCN2-
dependent action, we performed genome-wide expression
proﬁling of B16(F10) melanoma cells stably transfected with
CCN2 shRNA and scrambled control shRNA. We found that
the expression of 115 mRNAs was reduced 41.5-fold in
CCN2 shRNA–transfected B16(F10) melanoma cells
(Supplementary File online). The gene with the greatest
reduction in expression in CCN2 shRNA–transfected cells
was periostin, a matricellular protein previously implicated in
cell migration and shown to be dependent on CCN2
(Hamilton, 2008). Thus, we selected periostin for further
analysis. Loss of periostin from the tumor stroma of C57/BL6
mice deleted for CCN2 after 14 days of tumor growth was
conﬁrmed by immunohistochemical analysis using anti-
periostin antibody (Figure 4b). We conﬁrmed the decrease
in periostin expression in CCN2 knockdown B16(F10) cells
by real-time PCR and western blot analysis (Figure 5a).
Addition of recombinant periostin rescued the invasive defect
of CCN2-deﬁcient cells (Figure 5b and c). These results
suggest that the lack of invasive ability of CCN2-deﬁcient
melanoma cells is because of a lack of periostin expression.
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In human melanoma patient samples, CCN2 and POSTN
expression levels are correlated with stromal content and
each other
To investigate the role of CCN2 and POSTN in human
melanoma samples, we looked at the expression levels of
both genes in 104 primary and 368 metastatic melanoma
patient samples from The Cancer Genome Atlas (TCGA).
Stromal scores were calculated for each sample by the use of
the ESTIMATE (Estimation of STromal and Immune cells in
MAlignant Tumor tissues using Expression data) algorithm
(Yoshihara et al., 2013). We found that both CCN2 and
POSTN correlated strongly with stromal scores (r= 0.57 and
0.49, respectively), comparable to the strength of the corre-
lation between stromal scores and expression of ﬁbroblast
activation protein (r=0.57), the quintessential tumor-
associated stromal protein (Figure 6a and b; Supplementary
Figure 2 online). We also found that CCN2 and POSTN
expression positively correlated with each other (r= 0.33),
providing support for a relationship between CCN2 and
POSTN that extends to human melanoma patient samples
(Figure 6c). Intriguingly, CCN2 (Supplementary Figure 3A
and B online) and POSTN (Supplementary Figure 3C, D
online) expression did not correlate with the presence of
B-RAF mutations in melanoma patients. Conversely, CCN2
expression correlated with the activation state of protein
kinase C in human melanomas, and protein kinase C inhi-
bition reduced CCN2 mRNA expression in human and mouse
melanoma cells (Supplementary Figure 4A and B online).
Collectively, these data conﬁrm our in vitro and animal
studies and suggest that CCN2 and POSTN are highly
expressed in tumor stroma and that these matricellular
proteins are coregulated.
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Figure 1. Loss of CCN2 impairs the invasive ability of melanoma cells in vitro. B16(F10) murine melanoma cells were transfected with either CCN2 short
hairpin RNA (shRNA), to produce a knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to act as a control. (a) Cells treated with the CCN2 shRNA
lentiviral particles showed a signiﬁcant decrease in Ccn2 mRNA expression compared with both untreated B16(F10) cells and cells treated with the scrambled
control shRNA (n=3, **Po0.005) and a decrease in CCN2 protein present in the growth media. (b) Each cell line was subjected to a Boyden chamber assay to
assess their ability to invade through a collagen matrix. After being given 24 hours to invade through the collagen toward a chemotactic incentive, the
noninvasive cells and the collagen were removed, and the invasive cells were stained with DAPI (4',6-diamidino-2-phenylindole). (c) Cells deﬁcient in CCN2
were signiﬁcantly less invasive compared with both untreated B16(F10) cells and cells treated with the scrambled control shRNA (n=3, *Po0.05, **Po0.01).
Bar=100 μM.
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DISCUSSION
Our results demonstrate that CCN2 expression by tumor
stroma is required for melanoma metastasis. An emerging
concept is that alterations in the tumor microenvironment
promote invasion and metastasis, and thus targeting these
alterations may result in effective anticancer therapies (Jewer
et al., 2012; Quail et al., 2012). Matricellular proteins, such as
CCN2 and periostin, are secreted into the ECM, although they
are not considered to be structural components of the ECM.
Matricellular proteins are highly spatiotemporally regulated
and, as they alter cellular adhesive signaling responses
to ECM and growth factors, can have profound localized
effects on cellular behavior. The CCN family of matricellular
proteins, at least in part due to its ability to promote signaling
via integrins, has recently been proposed to have signiﬁcant
roles in altering the tumor microenvironment and hence
contributing to tumor growth and metastasis. Previous studies
have found that CCN2 is abundant in cancers such as
pancreatic cancer and that this overexpression is related to
cancer progression (Aikawa et al., 2006; Dornhofer et al.,
2006; Kondo et al., 2006; Bennewith et al., 2009; Sodek et al.,
2009; Mao et al., 2011). Our results showing that ﬁbroblast-
derived CCN2 contributes to melanoma metastasis suggest
that CCN2 may be a good target for drug intervention in
melanoma. Our data are consistent with and extend previous
data showing that CCN2 is upregulated in cancer cells in
response to hypoxia, oncogenic ras, and YAP/TAZ/hippo and
that an antibody against CCN2 blocks progression in animal
models of pancreatic cancer and melanoma (Aikawa et al.,
2006; Sha and Leask, 2011; Finger et al., 2014; Nallet-Staub
et al., 2014).
Periostin, similar to CCN2, is a matricellular protein
upregulated in conditions wherein the ECM is being
remodeled (Hamilton, 2008). Our data suggest that periostin
operates downstream of CCN2 to promote invasion and is
consistent with prior data using periodontal ligament cells that
showed rCCN2-induced periostin expression (Asano et al.,
2005); however, our data describe to our knowledge a
previously unreported link between CCN2 and periostin in
tumor metastasis. In this regard, it is interesting to note that
CCN2 appeared to be largely localized to the cell, whereas
periostin appeared to be present in the ECM. Previous data
have linked periostin expression with metastasis in various
tumors including invasive melanoma (Tilman et al., 2007;
Kotabuki et al., 2014). Moreover, periostin has been shown to
be upregulated in ﬁbroblasts in the tumor microenvironment
(Kikuchi et al., 2014), and studies indicate that it promotes the
invasiveness of pancreatic tumor cells (Baril et al., 2007).
Herein, we link tumor invasion in melanoma with periostin
expression, consistent with the notion that targeting periostin
may prove to be a viable anticancer therapy.
Overall, 40–60% of all cutaneous melanoma patients
possess position 600 mutations in BRAF; in these patients,
tumors shrink in response to the BRAF inhibitors vemurafenib
and dabrafenib (Fedorenko et al., 2015). However, patients
develop resistance to these drugs (Fedorenko et al., 2015).
That neither periostin nor CCN2 expression correlates with
BRAF mutations suggests that anti-periostin or anti-CCN2
therapies may represent viable therapeutic strategies with an
entirely different mechanism of action. Indeed, our data
suggest that cancer activated ﬁbroblasts may produce the
microenvironmental signals that are required for melanoma
tumors to metastasize in a fashion that is independent of BRAF
mutational status. As CCN2 expression appears to be
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Figure 2. CCN2 deﬁciency impairs the invasive ability in human C8161 cells.
C8161 cells were transfected with CCN2 small interfering RNA (siRNA), to
produce a knockdown in CCN2 expression, or scrambled siRNA, to act as a
control. (a and b) CCN2 siRNA–transfected C8161 cells and poorly aggressive
C81-61 show a signiﬁcant decrease in CCN2 mRNA and protein expression
when compared with cells treated with scrambled control siRNA. (c) Control
siRNA–transfected C8161 cells, CCN2 siRNA–transfected C8161 cells, and
C81-61 cells were subjected to a Boyden chamber assay to assess their
invasive ability. After being given 24 hours to invade toward a chemotactic
incentive, noninvasive cells were removed, and invasive cells were stained
with DAPI (4',6-diamidino-2-phenylindole). CCN2 siRNA–transfected
C8161 cells and C81-61 cells showed signiﬁcantly decreased invasion
compared with C8161 cells transfected with scrambled control siRNA (n=4,
**Po0.01, ****Po0.0001).
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Figure 3. Loss of CCN2 in tumor stroma ﬁbroblasts impairs metastasis in vivo. (a) Representative images of lung sections from wild-type or Ccn2-knockout mice
(mice deleted for CCN2 in ﬁbroblasts) following subcutaneous implantation with parental or CCN2 short hairpin RNA (shRNA) melanoma cells after 14 days of
tumor growth. Hematoxylin and eosin (H&E) staining detects sites of pulmonary metastasis by staining the dense metastatic foci purple (indicated by an arrow).
Bar=300 μM. (b) The graph quantiﬁes the total area of the lung section covered by metastases. Deletion of CCN2 in ﬁbroblasts of the recipient mice results in a
signiﬁcant decrease in metastasis compared with cells implanted into wild-type mice (N=8, *Po0.05). (c) Images of lungs ﬁxed with Bouin’s 21 days after tumor
growth of parental melanoma cells into wild-type or Ccn2-knockout mice. Bar= 3mM. Note dark areas indicating metastasized tumors, in wild-type but not in (d)
Ccn2-knockout mice (mice deleted for CCN2 in ﬁbroblasts). N=3, representative images are shown. Bar=3mM.
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Figure 4. Loss of CCN2 and periostin expression in tumor stroma in mice deleted for CCN2 in ﬁbroblasts. Sections of tumor stroma from wild-type or Ccn2-
knockout mice (mice deleted for CCN2 in ﬁbroblasts) stained with (a) anti-CCN2 or (b) anti-periostin antibody (N=3, representative images are shown). Mice
were examined after 14 days of tumor growth of parental melanoma cells or melanoma cells deleted for CCN2. Note that CCN2 appeared be localized to the cells
(red arrow), whereas periostin appeared to be localized to the matrix. Bar=50 μM.
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downstream of PKC, it is possible that CCN2 elicits its effects
by mediating combined protein kinase C/mitogen-activated
protein kinase or protein kinase C/Akt pathways (Musi et al.,
2014). Collectively, our data are consistent that blocking the
action of CCN2 produced by cancer activated ﬁbroblasts in
the stroma microenvironment may be a viable therapeutic
approach to mitigate the progression of melanoma.
MATERIALS AND METHODS
Cell culture and western blotting
B16(F10) murine melanoma cells were purchased (ATCC) and
cultured in high glucose Dulbecco’s modiﬁed Eagle’s medium,
10% fetal bovine serum (FBS), and 1% antibiotic/antimycotic
solution (Invitrogen, Burlington, ON, Canada). Cells were cultured
until conﬂuence before harvesting for mRNA or protein extraction.
Where indicated, cells were treated with 10 μM bisindolylmaleimide I,
a PKC inhibitor (EMD Millipore, Etobicoke, ON, Canada), for 6 hours
before RNA extraction. Cells were cultured until conﬂuence before
harvesting for mRNA or protein extraction. CCN2 levels were
detected by coincubating cultures with 50 μgml− 1 sodium heparin
(Sigma, St. Louis, MO). Sodium heparin was included to prevent
rapid internalization and degradation of CCN2 via LRP1, as
endogenous CCN2 can be rapidly degraded by mouse cells
(Segarini et al. 2001). One microliter conditioned culture medium
was collected for every treatment, and total protein was concentrated
using methanol/chloroform precipitation as described previously
(Friedman et al., 2009). Periostin protein levels were assessed by
extraction of total protein (using ice-cold TG lysis buffer (20 mM
Tris-HCl (pH 8), 1% Triton X-100, 10% glycerol, 137mM NaCl,
1.5 mM MgCl2, 1 mM EGTA, 50mM NaF, 1 mM Na3VO4, 1 mM
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Figure 5. Rescuing periostin deﬁciency rescues impaired invasion phenotype. B16(F10) melanoma cells were transfected with either CCN2 short hairpin RNA
(shRNA), to produce a knockdown in Ccn2 mRNA expression, or a scrambled shRNA, to act as a control. (a) Cells treated with the CCN2 shRNA showed a
signiﬁcant decrease in Postn mRNA and protein expression compared with cells treated with scrambled control shRNA. (b) Cells treated with Ccn2 shRNA were
treated with 150 ngml−1 rPOSTN and subjected to a Boyden chamber assay to assess their ability to invade through a collagen matrix. After being given 24 hours
to invade through the collagen toward a chemotactic incentive, the noninvasive cells and the collagen were removed, and the invasive cells were stained with
DAPI (4',6-diamidino-2-phenylindole). (c) Cells treated with 150 ngml−1 rPOSTN showed a rescue of the impaired invasion phenotype displayed by Ccn2
shRNA–treated cells (n=3, **Po0.01). Bar= 100 μM.
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phenylmethylsulfonyl ﬂuoride, 20 μM leupeptin, 10 μg of aprotinin
ml−1)). The concentration of protein was detected (Life Technolo-
gies, Burlington, ON, Canada), and equal amounts of protein
(100 μg) were subjected to SDS-PAGE on a 4–12% gradient gel
(Invitrogen). Gels were then blotted onto nitrocellulose (BioRad,
Missassauga, ON, Canada), and CCN2 was detected using a goat
anti-CCN2 antibody (1:200 dilution; Santa Cruz, Toronto, ON,
Canada), followed by a horseradish peroxidase–conjugated anti-goat
antibody (1:2000; Jackson, West Grove, PA), a chemiluminescent
detection kit (Life Technologies), and a X-Ray ﬁlm (Kodak, Toronto,
ON, Canada). Alternatively, Periostin was detected using a rabbit
anti-POSTN (1:1000 dilution; Santa Cruz) followed by a horseradish
peroxidase–conjugated anti-rabbit antibody (1:2000; Jackson), a
chemiluminescent detection kit (Life Technologies), and a X-Ray
ﬁlm (Kodak). When indicated, cells were transfected with connective
tissue growth factor (CCN2) shRNA lentiviral or control shRNA
lentiviral particles (Santa Cruz) using polybrene and selected for
using puromycin as described by the manufacturer (Santa Cruz).
Real-time RT-PCR
B16(F10) murine melanoma cells were grown in high glucose
Dulbecco’s modiﬁed Eagle’s medium containing 10% FBS until 75%
conﬂuence after which the medium was replaced with low glucose
Dulbecco’s modiﬁed Eagle’s medium containing 0.5% FBS and
grown for 24 hours. RNA was harvested using Trizol (Invitrogen) and
used for Real-Time RT-PCR. An amount of 25 ng of RNA was reverse
transcribed and ampliﬁed using TaqMan Assays on Demand (Life
Technologies) in a 15 μl reaction containing primers for mouse CCN2
and POSTN (Assays on Demand; Life Technologies) and 6-
carboxyﬂuroscein-labeled TaqMan MGB probe. Reverse Transcrip-
tase One-Step Mastermix was added to samples, and the ABI Prism
7900 HT sequence detector (Life Technologies) was used according
to the manufacturer’s instructions to detect ampliﬁed sequences.
Samples were run in triplicate; expression values were standardized
to control values from EUK18S primers using the ΔΔCt method.
Statistical analysis was performed using one-way analysis of variance
and Tukey’s post hoc test on GraphPad Software (Graftpad,
La Jolla, CA).
Expression proﬁling
Expression proﬁling was performed as described in prior publications
(Guo et al., 2011a, b). All sample labeling and processing were
handled at the London Regional Genomics Centre (Robarts Research
Institute, London, ON, Canada; http://www.lrgc.ca). Brieﬂy, RNA
quality was assessed on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Missassauga, ON, Canada) and the RNA 6000 Nano
Kit (Caliper Life Sciences, Hopkinton, MA) before 5.5 μg of single-
stranded cDNA was synthesized from 200 ng of total RNA, end
labeled, and hybridized, for 16 hours at 45 °C, to Human Gene 1.0
ST arrays. GeneChips were scanned with the GeneChip Scanner
3000 7G, and probe level (.CEL ﬁle) data were generated using
Affymetrix Command Console v.3.2.4. Probes were summarized to
gene level data in Partek Genomics Suite v6.6 (Partek, St. Louis, MO)
using the RMA algorithm. Experiments were performed two times,
and fold changes and P-values were generated using analysis of
variance in Partek. Genes that signiﬁcantly changed (at least 1.5-fold
change, P-value o0.05) in response to CCN2 knockdown were
compiled and exported into DAVID (http://david.abcc.ncifcrf.gov/)
for further analysis.
Immunohistochemistry
Tissue was stained for CCN2 and Periostin using the Vectastain ABC
Kit (Vector Laboratories, Burlington, ON, Canada). Brieﬂy, sections
(0.5 μm) were cut using a microtome (Leica, Concord, ON, Canada),
collected on Superfrost Plus slides (Fisher Scientiﬁc, Ottawa, ON,
Canada), dewaxed in xylene, and rehydrated by successive immer-
sion in descending concentrations of alcohol. Antigen retrieval was
performed by immersing slides in Na-citrate solution (pH 6.0)
for 30minutes at 98 °C. After cooling, slides were rinsed, and
nonspeciﬁc binding was blocked by incubation with diluted normal
serum. Sections were incubated with primary antibodies in diluted
normal serum (1:100 goat anti-CCN2 or 1:100 rabbit anti-POSTN),
followed by incubation with biotinylated secondary antibody
solution and Vectastain ABC Reagent. After incubation, the sections
were incubated in ImmPACT DAB peroxidise substrate (Vector
Laboratories) and counterstained with hematoxylin.
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Figure 6. CCN2 and POSTN expression levels correlate with stromal content. Stromal scores for primary (n= 104) and metastatic (n= 368) melanoma patient
samples from The Cancer Genome Atlas (TCGA) were calculated by the use of the ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor
tissues using Expression data) method. Stromal scores were analyzed for correlation with (a) CCN2 and (b) POSTN gene expression values (log 10 (RSEM (RNA-
Seq by Expectation-Maximization) normalized count)) as determined by RNA sequencing (Illumina HiSeq 2000 RNA Sequencing Version 2 analysis). Both CCN2
and POSTN were found to strongly correlate with the stromal scores (r= 0.57 and 0.49, respectively). (c) Scatterplot comparison of CCN2 and POSTN gene
expression values (log 10 (RSEM normalized count)) revealed a correlation between the expression of these two genes in patient samples (r=0.33). Rug plots
show the density of the data for given values.
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In vitro invasion assay
A total of 10,000 cells (parental, CCN2 shRNA, control shRNA B16
(F10), C8161 CCN2 siRNA, C8161 control siRNA, or C81-61 cells)
were seeded in growth medium containing 0.5% FBS (and 5 μgml− 1
puromycin hydrochloride for shRNA cells) onto a transwell ﬁlter
insert with a pore size of 8 μm coated with 100 μl of 10 μgml− 1
puriﬁed bovine collagen (Advanced Biosystems, Redwood City, CA)
as described previously (Chen, 2005). The transwell ﬁlter insert was
suspended in a plate ﬁlled with growth medium containing 10% FBS
(to create a chemotactic incentive to invade) and allowed to incubate
at 37 °C for 24 hours. After incubation, all excess collagen and
noninvasive cells were removed from the inside of the transwell ﬁlter
insert. The remaining cells were ﬁxed in methanol and stained
with 1 μg ml−1 DAPI (4',6-diamidino-2-phenylindole) to allow for
counting with microscopy.
In vitro proliferation assay
Parental B16(F10), CCN2 shRNA–treated, and control shRNA–
treated cells were assayed with the BrdU Cell Proliferation Assay
Kit as described by the manufacturer (Cell Signaling, Whitby, ON,
Canada). Brieﬂy, this involves growing the cells in 96-well plates
(~1,000 cells per well) in the presence of 5-bromo-2'-dioxyuridine
(BrdU), which is incorporated into the DNA of proliferating cells in
the place of thymidine. After being allowed to proliferate in the
presence of BrdU for 0, 6, and 24 hours, the cells were ﬁxed, and the
DNA is denatured. An anti-BrdU antibody along with a horseradish
peroxidase–conjugated secondary antibody and a TMB substrate
were used to determine the levels of BrdU incorporated into the
cells by detection using a microplate reader at ~ 420 nm wavelength
(Bio-Rad).
Animals
Mice possessing a tamoxifen-dependent Cre recombinase under the
control of a ﬁbroblast-speciﬁc regulatory sequence from the proα2(I)
collagen gene were crossed with mice homozygous for a conditional
CCN2 allele to generate Cre/CCN2 heterozygote mice, which were
mated to generate mice hemizygous for Cre and homozygous for
CCN2. Animals used for experiments were genotyped by PCR as
described previously (Zheng et al., 2002; Liu et al., 2011). To delete
CCN2 (CCN2− /−) in ﬁbroblasts, 3-week-old mice were given
intraperitoneal injections of tamoxifen suspension (0.1 ml of 10
mgml−1 4-hydroxitamoxifen; Sigma) over 5 days. Littermate
mice of identical genotype were injected with corn oil and
were used as controls (CCN2ﬂ/ﬂ). All animal protocols were approved
by the animal care committee at the University of Western
Ontario.
In vivo tumor growth and metastasis
Subconﬂuent melanoma cells in the exponential growth phase were
harvested by exposure to 0.25% trypsin/0.02% EDTA solution,
resuspended in serum-free Dulbecco’s modiﬁed Eagle’s medium at a
concentration of 3300 cells per μl, and 330,000 cells were injected
subcutaneously into the right ﬂank of each mouse. Upon appearance
of a palpable tumor, the volume of the tumor was measured daily
using calipers and the following equation: tumor volume (mm3)= 1/2
(length of longest tumor dimension)× (length of narrowest tumor
dimension)2. Tumor growth was evaluated over the course of
14 days, and mice were killed on the 14th day. After killing, the
lungs and tumor were collected from the mice and ﬁxed in a 4%
paraformaldehyde solution. After ﬁxation, tissues were processed,
embedded in parafﬁn, and prepared for histological sectioning. Lung
sections were stained with hematoxylin and eosin (Fisher Scientiﬁc)
to locate dense metastatic foci. Three non-serial sections per lung
were examined. To examine macroscopic metastasis in the lungs,
tumors were allowed to grow for 21 days, and collected lungs were
stained with Bouin’s solution and rinsed with 70% ethanol to
visualize the metastases.
Data sets and analysis of patient samples
Level 3 TCGA SKCM RNAseqV2 gene expression data were obtained
from the TCGA Data Portal in March 2015 and represent RSEM
(RNA-Seq by Expectation-Maximization) normalized counts. SKCM
TCGA mutational data were obtained from the USCS Xena browser
for calls generated at the Broad Institute Genome Sequencing Center
using the MutDect method in April 2015 (genome cancer.ucsc.edu/
download/public/xena/TCGA/TCGA.SKCM.sampleMap/mutation_
broad). Level 3 TCGA RPPA data were obtained from the TCGA
Data Portal in March 2015 and represent log 2 median-centered
linear after normalization values.
Stromal and immune scores were deﬁned for tumors by the
ESTIMATE algorithm using tumor RNASeqV2 data and the ESTIMATE
package in R (Yoshihara et al., 2013). Pearson’s correlation
coefﬁcient was used to calculate the association of speciﬁc genes
to stromal signatures and to each other.
We conducted all analyses and visualizations in the RStudio
programming environment (v.0.98.501). R/Bioconductor packages
ggplot2, plyr, and ESTIMATE were used where appropriate.
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